Kenvue Inc. (KVUE)
- Previous Close
20.45 - Open
20.51 - Bid --
- Ask --
- Day's Range
20.36 - 20.61 - 52 Week Range
17.82 - 27.80 - Volume
12,673,032 - Avg. Volume
16,962,990 - Market Cap (intraday)
39.327B - Beta (5Y Monthly) --
- PE Ratio (TTM)
24.16 - EPS (TTM)
0.85 - Earnings Date --
- Forward Dividend & Yield 0.80 (3.89%)
- Ex-Dividend Date May 7, 2024
- 1y Target Est
22.17
Kenvue Inc. operates as a consumer health company worldwide. The company operates through three segments: Self Care, Skin Health and Beauty, and Essential Health. The Self Care segment offers cough, cold and allergy, pain care, digestive health, smoking cessation, eye care, and other products under the Tylenol, Motrin, Benadryl, Nicorette, Zarbee's, ORSLTM, Rhinocort, Calpol, and Zyrtec brands. The Skin Health and Beauty segment provides face and body care, hair, sun, and other care products under the Neutrogena, Aveeno, Dr.Ci:Labo, Le Petit Marseillais, Lubriderm, Rogaine, and OGX brand names. The Essential Health segment offers oral and baby, women's health, wound, and other care products under the Listerine, Johnson's, Band-Aid, and Stayfree, o.b., tampons, Carefree, and Desitin Diaper Rash brands. The company was incorporated in 2022 and is headquartered in Skillman, New Jersey.
www.kenvue.com22,000
Full Time Employees
December 31
Fiscal Year Ends
Sector
Industry
Recent News: KVUE
Performance Overview: KVUE
Trailing total returns as of 5/9/2024, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: KVUE
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: KVUE
Valuation Measures
Market Cap
39.15B
Enterprise Value
46.20B
Trailing P/E
24.02
Forward P/E
17.79
PEG Ratio (5yr expected)
2.25
Price/Sales (ttm)
2.53
Price/Book (mrq)
3.49
Enterprise Value/Revenue
2.98
Enterprise Value/EBITDA
18.94
Financial Highlights
Profitability and Income Statement
Profit Margin
9.63%
Return on Assets (ttm)
--
Return on Equity (ttm)
--
Revenue (ttm)
15.49B
Net Income Avi to Common (ttm)
1.49B
Diluted EPS (ttm)
0.85
Balance Sheet and Cash Flow
Total Cash (mrq)
1.38B
Total Debt/Equity (mrq)
75.17%
Levered Free Cash Flow (ttm)
--
Research Analysis: KVUE
Company Insights: KVUE
KVUE does not have Company Insights